Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025

作者：Aaron M. Frutos, Seana Cleary, Emily Reeves, Haris M. Ahmad, Ashley M. Price, Wesley H. Self, Yuwei Zhu, Basmah Safdar, Ithan D. Peltan, Kevin W. Gibbs, Matthew C. Exline, Adam S. Lauring, Sarah Ball, Malini B. DeSilva, Sara Y. Tartof, Kristin Dascomb, Stephanie A. Irving, Nicola P. Klein, Brian E. Dixon, Toan C. Ong, Ivana A. Vaughn, Stacey L. House, Kiran A. Faryar, Mary Patricia Nowalk, Manjusha Gaglani, Karen J. Wernli, Vel Murugan, Olivia L. Williams, Rangaraj Selvarangan, Geoffrey A. Weinberg, Mary Allen Staat, Natasha Halasa, Leila C. Sahni, Marian G. Michaels, Janet A. Englund, Marie K. Kirby, Diya Surie, Fatimah S. Dawood, Benjamin R Clopper, Heidi L. Moline, Ruth Link‐Gelles, Amanda B. Payne, Elizabeth Harker, Kristina Wielgosz, Zachary A. Weber, Duck‐Hye Yang, Nathaniel M. Lewis, Jennifer DeCuir, Samantha M. Olson, Jessie R. Chung, Brendan Flannery, Lisa A. Grohskopf, Carrie Reed, Shikha Garg, Sascha Ellington, CDC Influenza Vaccine Effectiveness Collaborators, CDC Influenza Vaccine Effectiveness Collaborators, Laurence W. Busse, Cristie Columbus, Abhijit Duggal, Adit A. Ginde, Michelle N. Gong, David N. Hager, Estelle S. Harris, Cassandra Johnson, Nicholas J. Johnson, Akram Khan, Jennie H. Kwon, Christopher Mallow, Nicholas M. Mohr, Jarrod Mosier, Matthew E. Prekker, Nida Qadir, Colleen Ratcliff, Nathan I. Shapiro, Jay S. Steingrub, Jennifer G. Wilson, Omobosola Akinsete, Michelle A. Barron, Daniel Bride, Tom Duszynski, Shaun J. Grannis, John Hansen, Pradeep Koppolu, David Mayer, Charlene McEvoy, Allison L. Naleway, St Salas, Tamara Sheffield, Lina S. Sy, Ousseny Zerbo, Julie A. Boom, Megan Freeman, Eileen J. Klein, Mary E. Moffatt, Daniel C. Payne, Pedro A. Piedra, Elizabeth P. Schlaudecker, Jennifer E. Schuster, Laura S Stewart, Peter G. Szilagyi, John V. Williams, Danielle M. Zerr, G.K. Balasubramani, Natalie A.B. Bontrager, Tara Curley, Curtis J. Donskey, Juliana DaSilva, Britan Fairall, Krissy Moehling Geffel, Claudia K. Hoyen, Lisa M. Keong, Erika Kiniry, Aleda M. Leis, Emily T. Martin, Jamie Mills, Lora Nordstrom, Leah Odame‐Bamfo, C. Hallie Phillips, Emmanuel B. Walter, Karen Yeager · 发表于：MMWR Morbidity and Mortality Weekly Report · 年份：2025 · DOI：10.15585/mmwr.mm7406a2 · 被引用次数：62 · 研究领域：Influenza Virus Research Studies、Vaccine Coverage and Hesitancy、Viral Infections and Outbreaks Research

Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim influenza vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during the 2024-25 influenza season (October 2024-February 2025). Among children and adolescents aged <18 years, VE against any influenza was 32%, 59%, and 60% in the outpatient setting in three networks, and against influenza-associated hospitalization was 63% and 78% in two networks. Among adults aged ≥18 years, VE in the outpatient setting was 36% and 54% in two networks and was 41% and 55% against hospitalization in two networks. Preliminary estimates indicate that receipt of the 2024-2025 influenza vaccine reduced the likelihood of medically attended influenza and influenza-associated hospitalization. CDC recommends annual receipt of an age-appropriate influenza vaccine by all eligible persons aged ≥6 months as long as influenza viruses continue to circulate locally.